[
  {
    "ts": null,
    "headline": "GLP drugs and peptides are changing more than weight loss",
    "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. GLP drugs are about far more than weight loss—and the next wave of peptides could redefine preventative health. On this subclip from Trader Talk, Futurum CEO Daniel Newman explains how peptides act as biological signals that help restore functions the body no longer performs efficiently, from metabolism to recovery and cognitive health. The conversation also ties peptide innovation to AI-driven drug discovery and the growing role of companies like Eli Lilly (LLY) in advancing next-generation GLP therapies. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
    "url": "https://finnhub.io/api/news?id=70ad4b6449fa5cfe47fea62745276e91481bddf6426c53f34b63379153303fa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769630572,
      "headline": "GLP drugs and peptides are changing more than weight loss",
      "id": 138289059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. GLP drugs are about far more than weight loss—and the next wave of peptides could redefine preventative health. On this subclip from Trader Talk, Futurum CEO Daniel Newman explains how peptides act as biological signals that help restore functions the body no longer performs efficiently, from metabolism to recovery and cognitive health. The conversation also ties peptide innovation to AI-driven drug discovery and the growing role of companies like Eli Lilly (LLY) in advancing next-generation GLP therapies. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
      "url": "https://finnhub.io/api/news?id=70ad4b6449fa5cfe47fea62745276e91481bddf6426c53f34b63379153303fa6"
    }
  },
  {
    "ts": null,
    "headline": "Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25%",
    "summary": "Exploring Strategic Moves in the Health Sciences Sector",
    "url": "https://finnhub.io/api/news?id=b00643a6ece6e4288e757176912e4ee8a6d97fc886d02fec06ed618271100b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769630481,
      "headline": "Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25%",
      "id": 138289060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Exploring Strategic Moves in the Health Sciences Sector",
      "url": "https://finnhub.io/api/news?id=b00643a6ece6e4288e757176912e4ee8a6d97fc886d02fec06ed618271100b95"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
    "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
    "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622420,
      "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
      "id": 138287497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
      "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership",
    "summary": "Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.",
    "url": "https://finnhub.io/api/news?id=a59aa446eed2a23a923fc02afe556572003e6847961106544cb8bd5a13ffa2ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622030,
      "headline": "Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership",
      "id": 138287498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.",
      "url": "https://finnhub.io/api/news?id=a59aa446eed2a23a923fc02afe556572003e6847961106544cb8bd5a13ffa2ac"
    }
  },
  {
    "ts": null,
    "headline": "Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=efa4f4fda1c5f75cc92404e9851b5c0c9f7608643ac822937fbf0c6eed0835d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769620201,
      "headline": "Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?",
      "id": 138287499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=efa4f4fda1c5f75cc92404e9851b5c0c9f7608643ac822937fbf0c6eed0835d0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=8ab57ee15b6e835a3232c9a8fb8ca3261c4b13edc9fdefc2914dc42278c0a571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612408,
      "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 138285024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=8ab57ee15b6e835a3232c9a8fb8ca3261c4b13edc9fdefc2914dc42278c0a571"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “Chatter” About NVIDIA (NVDA)’s Circular Deals is “Nonsense”",
    "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks on Jim Cramer’s radar. NVIDIA Corporation (NASDAQ:NVDA) is a regular stock on Jim Cramer’s radar. The CNBC TV host is one of the stock’s biggest proponents. As January kicked off, Citi reiterated a Buy rating on the shares […]",
    "url": "https://finnhub.io/api/news?id=a695ccf9867d9a976adb6d6ba08cc403a1e7de481866ae6f4626fb756396541c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612088,
      "headline": "Jim Cramer Says “Chatter” About NVIDIA (NVDA)’s Circular Deals is “Nonsense”",
      "id": 138281348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks on Jim Cramer’s radar. NVIDIA Corporation (NASDAQ:NVDA) is a regular stock on Jim Cramer’s radar. The CNBC TV host is one of the stock’s biggest proponents. As January kicked off, Citi reiterated a Buy rating on the shares […]",
      "url": "https://finnhub.io/api/news?id=a695ccf9867d9a976adb6d6ba08cc403a1e7de481866ae6f4626fb756396541c"
    }
  },
  {
    "ts": null,
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611689,
      "headline": "Some of Pharma's Biggest Brands Face a New Reality",
      "id": 138281443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A government process quietly moves forward",
      "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets",
    "summary": "Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene editing therapies for hearing loss. The company also received FDA Breakthrough Therapy designation for an antibody drug conjugate in ovarian cancer. Both developments expand Lilly’s pipeline into genetic hearing loss and oncology, beyond its current strength in diabetes and obesity treatments. Eli Lilly, best known to many investors for its diabetes and obesity portfolio,...",
    "url": "https://finnhub.io/api/news?id=58e77e5b6c5cf2c7355055fbba9ddb0d8de8f0a209042595599b4ad449f58537",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609507,
      "headline": "Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets",
      "id": 138281444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene editing therapies for hearing loss. The company also received FDA Breakthrough Therapy designation for an antibody drug conjugate in ovarian cancer. Both developments expand Lilly’s pipeline into genetic hearing loss and oncology, beyond its current strength in diabetes and obesity treatments. Eli Lilly, best known to many investors for its diabetes and obesity portfolio,...",
      "url": "https://finnhub.io/api/news?id=58e77e5b6c5cf2c7355055fbba9ddb0d8de8f0a209042595599b4ad449f58537"
    }
  },
  {
    "ts": null,
    "headline": "Lilly bets on Seamless, delving further into genetic medicine for hearing loss",
    "summary": "The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.",
    "url": "https://finnhub.io/api/news?id=752b3e988b2a864f8ac27d896413a31b51ee856e8a8f14276c1b5cedce6ac589",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609340,
      "headline": "Lilly bets on Seamless, delving further into genetic medicine for hearing loss",
      "id": 138287500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.",
      "url": "https://finnhub.io/api/news?id=752b3e988b2a864f8ac27d896413a31b51ee856e8a8f14276c1b5cedce6ac589"
    }
  },
  {
    "ts": null,
    "headline": "Roche Reports Upbeat Efficacy Data From Phase II Obesity Study",
    "summary": "RHHBY reports encouraging phase II data as CT-388 delivers strong, sustained weight loss and metabolic benefits in adults with obesity or overweight.",
    "url": "https://finnhub.io/api/news?id=55679358e9c27a7ad21938876119b0b6b8b5a011a37355bf4f4d1bd75b62abb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609340,
      "headline": "Roche Reports Upbeat Efficacy Data From Phase II Obesity Study",
      "id": 138281445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RHHBY reports encouraging phase II data as CT-388 delivers strong, sustained weight loss and metabolic benefits in adults with obesity or overweight.",
      "url": "https://finnhub.io/api/news?id=55679358e9c27a7ad21938876119b0b6b8b5a011a37355bf4f4d1bd75b62abb4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,039.51 as of January 27th. LLY’s trailing and forward P/E were 50.93 and 31.65 respectively according to Yahoo Finance. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. LLY presents a […]",
    "url": "https://finnhub.io/api/news?id=1c469313c36aa94a4c57bd3a3325f61196413411589b844e064a17d73f0c07a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769608855,
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "id": 138281446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Eli Lilly and Company on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,039.51 as of January 27th. LLY’s trailing and forward P/E were 50.93 and 31.65 respectively according to Yahoo Finance. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. LLY presents a […]",
      "url": "https://finnhub.io/api/news?id=1c469313c36aa94a4c57bd3a3325f61196413411589b844e064a17d73f0c07a8"
    }
  },
  {
    "ts": null,
    "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=1b4771bfe0175671597a44d93ff2b0bea06eed6c42a888366a98a1405d430cbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769608804,
      "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
      "id": 138281447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=1b4771bfe0175671597a44d93ff2b0bea06eed6c42a888366a98a1405d430cbc"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Eli Lilly (LLY) is Surging",
    "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can be downloaded here. Global equity markets delivered robust results in the quarter, backed by easing inflation trends and strong economic data. The Hardman Johnston Global Equity Strategy […]",
    "url": "https://finnhub.io/api/news?id=366365e6d4ab65a025564021b4476534d6cba8ae4d6dea79c113eb5a02557ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769605394,
      "headline": "Here’s Why Eli Lilly (LLY) is Surging",
      "id": 138280574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can be downloaded here. Global equity markets delivered robust results in the quarter, backed by easing inflation trends and strong economic data. The Hardman Johnston Global Equity Strategy […]",
      "url": "https://finnhub.io/api/news?id=366365e6d4ab65a025564021b4476534d6cba8ae4d6dea79c113eb5a02557ea9"
    }
  },
  {
    "ts": null,
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604538,
      "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
      "id": 138280575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
      "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Investors May Be In For An Earnings Surprise",
    "summary": "Novo Nordisk: Investors May Be In For An Earnings Surprise",
    "url": "https://finnhub.io/api/news?id=37d1092f0a5b38958a2822acbfe279b171103bbb6eda78ffd71411727b687248",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769603967,
      "headline": "Novo Nordisk: Investors May Be In For An Earnings Surprise",
      "id": 138283782,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=37d1092f0a5b38958a2822acbfe279b171103bbb6eda78ffd71411727b687248"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
    "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.",
    "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769602052,
      "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
      "id": 138282758,
      "image": "https://image.cnbcfm.com/api/v1/image/107188275-16753645842023-02-02t183236z_737430976_rc253z9n9jw3_rtrmadp_0_lilly-results.jpeg?v=1694350801&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement. ",
      "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless",
    "summary": "drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, ​the Germany-based startup said on Wednesday, to develop and commercialize ‌treatments for hearing loss using the biotech's gene-editing platform.",
    "url": "https://finnhub.io/api/news?id=5e913b750a7969590bcd98558aa20282c398c7a74026f0e1a741cd34acaf31c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601800,
      "headline": "Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless",
      "id": 138280576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, ​the Germany-based startup said on Wednesday, to develop and commercialize ‌treatments for hearing loss using the biotech's gene-editing platform.",
      "url": "https://finnhub.io/api/news?id=5e913b750a7969590bcd98558aa20282c398c7a74026f0e1a741cd34acaf31c6"
    }
  },
  {
    "ts": null,
    "headline": "Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss",
    "summary": "-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders -- -- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications -- Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global re",
    "url": "https://finnhub.io/api/news?id=31ed05a889fed0e4844795ea69e9ded12f7c82db1e7dbf6c2772fc6dea577049",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601600,
      "headline": "Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss",
      "id": 138280577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders -- -- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications -- Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global re",
      "url": "https://finnhub.io/api/news?id=31ed05a889fed0e4844795ea69e9ded12f7c82db1e7dbf6c2772fc6dea577049"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "1131 GMT – Roche Holding’s results from a midstage study of its CT-388 obesity drug candidate look promising, UBS analysts say in a research note.  The drug the Swiss pharmaceutical company is developing achieved weight-loss efficacy that seems to be broadly similar to Eli Lilly’s Zepbound, but at an earlier timepoint, and the discontinuation rate looks similar too, UBS says.  “All that said, the weight loss looks robust and the safety profile looks generally consistent with the drug class.”",
    "url": "https://finnhub.io/api/news?id=501373ecc47e8911c6338ef890a47c62c730cedd7db67f01629cb52c3f9c66e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769600580,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138280578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "1131 GMT – Roche Holding’s results from a midstage study of its CT-388 obesity drug candidate look promising, UBS analysts say in a research note.  The drug the Swiss pharmaceutical company is developing achieved weight-loss efficacy that seems to be broadly similar to Eli Lilly’s Zepbound, but at an earlier timepoint, and the discontinuation rate looks similar too, UBS says.  “All that said, the weight loss looks robust and the safety profile looks generally consistent with the drug class.”",
      "url": "https://finnhub.io/api/news?id=501373ecc47e8911c6338ef890a47c62c730cedd7db67f01629cb52c3f9c66e6"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
    "url": "https://finnhub.io/api/news?id=d820259e38faa5d65bd840b433fdc2658c6204f792aeefcd229d1f393beb7439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769599881,
      "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
      "id": 138279754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
      "url": "https://finnhub.io/api/news?id=d820259e38faa5d65bd840b433fdc2658c6204f792aeefcd229d1f393beb7439"
    }
  },
  {
    "ts": null,
    "headline": "India Obesity Drug Fight Is About to Intensify",
    "summary": "Sun Pharma clears path for semaglutide generics",
    "url": "https://finnhub.io/api/news?id=721b182491ae683fce91f03c6c5f0a1d3c23f6a24eb91ea709c9ea4a8dc93033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769599878,
      "headline": "India Obesity Drug Fight Is About to Intensify",
      "id": 138279755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sun Pharma clears path for semaglutide generics",
      "url": "https://finnhub.io/api/news?id=721b182491ae683fce91f03c6c5f0a1d3c23f6a24eb91ea709c9ea4a8dc93033"
    }
  },
  {
    "ts": null,
    "headline": "Eikon ‍Therapeutics targets $908 million valuation in US IPO",
    "summary": "Jan 28 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.",
    "url": "https://finnhub.io/api/news?id=9e364e68879b188c802a84227ed88c2537b4723a73dca118c3060ed83c4882ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769599559,
      "headline": "Eikon ‍Therapeutics targets $908 million valuation in US IPO",
      "id": 138279756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Jan 28 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.",
      "url": "https://finnhub.io/api/news?id=9e364e68879b188c802a84227ed88c2537b4723a73dca118c3060ed83c4882ea"
    }
  },
  {
    "ts": null,
    "headline": "AI isn't a bubble but the real upside is shifting",
    "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. What if the AI boom is just getting started? On this episode of Trader Talk, Kenny Polcari sits down with tech analyst Daniel Newman to break down why AI is still in its earliest innings—and why market leadership is starting to broaden beyond the Magnificent Seven. They unpack the implications of the Nvidia (NVDA) and Eli Lilly (LLY) partnership, enterprise AI adoption, and where investors may find the next wave of alpha as the trade widens. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
    "url": "https://finnhub.io/api/news?id=52c891c47d783718fff4163e0494752f46a30ab1c0bb0658712123cfd83f749f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769598057,
      "headline": "AI isn't a bubble but the real upside is shifting",
      "id": 138285025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. What if the AI boom is just getting started? On this episode of Trader Talk, Kenny Polcari sits down with tech analyst Daniel Newman to break down why AI is still in its earliest innings—and why market leadership is starting to broaden beyond the Magnificent Seven. They unpack the implications of the Nvidia (NVDA) and Eli Lilly (LLY) partnership, enterprise AI adoption, and where investors may find the next wave of alpha as the trade widens. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
      "url": "https://finnhub.io/api/news?id=52c891c47d783718fff4163e0494752f46a30ab1c0bb0658712123cfd83f749f"
    }
  },
  {
    "ts": null,
    "headline": "Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips",
    "summary": "Rocheâs Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out why RHHBY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=8f9039a4eb1f612ca0689c32add71ce58bac83fad04935681f7e278c3022e295",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769590571,
      "headline": "Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips",
      "id": 138280984,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232349278/image_2232349278.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Rocheâs Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out why RHHBY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=8f9039a4eb1f612ca0689c32add71ce58bac83fad04935681f7e278c3022e295"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
    "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
    "url": "https://finnhub.io/api/news?id=79024cc328035c267555da15b793d65a2e14c9292aeb18b82f3ab260b331d0f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769587519,
      "headline": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
      "id": 138279083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
      "url": "https://finnhub.io/api/news?id=79024cc328035c267555da15b793d65a2e14c9292aeb18b82f3ab260b331d0f0"
    }
  }
]